Non-alcoholic Steatohepatitis Registry Platform Study
Trial Snapshot
- Phase
- Not Applicable
- Status
- Terminated
- Sponsor
- AstraZeneca
- Enrollment
- 1,122
- Locations
- 16
- Primary Endpoint
- 1.Patient demography
Study Overview
Brief Summary
This is a multi-center, prospective, observational registry platform study aimed at describing the clinical characteristics and diagnosis and treatment patterns of Chinese patients with nonalcoholic steatohepatitis (NASH) with fibrosis.
Detailed Description
Non-alcoholic fatty liver disease (NAFLD) is a metabolic stress-induced liver injury closely related to insulin resistance and genetic susceptibility, and its disease spectrum includes non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma (HCC). NASH is a severe form of NAFLD, defined as more than 5% hepatocellular steatosis combined with intralobular inflammation and hepatocellular ballooning degeneration. By conducting research on the NASH patient registry platform and collecting real-world data on the clinical characteristics and diagnosis and treatment patterns of NASH patients, including demographics, clinical characteristics, treatment, outcomes, healthcare utilization, lifestyle, and genotype, on the one hand, it can provide evidence of scientific value for clinical practice and formulate diagnosis and treatment guidelines, and on the other hand, it can promote the clinical development of NASH drugs in China.
This is a multi-center, prospective, observational registry platform study. Patient recruitment is tentatively scheduled from December 2023 to December 2024. NASH with fibrosis that meets the inclusion criteria but does not meet the exclusion criteria will be consecutively enrolled in the selected center. The estimated number of patients is 2,500, which will be adjusted according to the progress of research. Among these subjects, information on two genes, PNPLA3 and HSD17B13, will be collected from approximately 500 NASH patients with fibrosis stage F2 or higher.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •(1) Subjects must be between 18 and 75 years old when signing the informed consent form, and must have the ability to sign the consent form independently; (2) NASH patients who meet one of the following conditions:
- •Liver biopsy was performed within 24 months before enrollment, and the pathological diagnosis was NASH and the fibrosis stage was F2 or above;
- •FibroScan-AST (FAST) score ≥ 0.30 within 24 months before enrollment;
- •There are any of the following evidences of fatty liver
- •Controlled attenuation parameter (CAP) > 285 dB/m within 24 months before enrollment;
- •Liver ultrasonography showed fatty liver within 24 months before enrollment;
- •Magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) examination within 24 months before enrollment showed liver fat fraction ≥ 5%; and any of the following evidence of liver fibrosis
- •Liver stiffness measurement (LSM) ≥ 7.5kPa by vibration-controlled transient elastography (VCTE) within 24 months before enrollment;
- •The elasticity value of magnetic resonance elastography (MRE) examination within 24 months before enrollment is ≥2.93kPa;
- •If there is no liver biopsy and no liver elastography equipment is available in the research center, FIB-4>1.3 (under 65 years old) or>2 (over 65 years old) within 3 months before enrollment.
Exclusion Criteria
- •History of liver transplantation;
- •Patients with bleeding tendency or coagulation dysfunction (for example, bleeding tendency, such as hemophilia, suspected hemangioma or suspected hydatid infection);
- •Exclude liver diseases caused by the following causes: alcoholic steatohepatitis, drug-induced, viral or autoimmune hepatitis, primary hemochromatosis, α1-antitrypsin deficiency, hepatolenticular degeneration, hypothyroidism, inflammatory bowel disease, Cushing's syndrome, celiac disease, β lipoprotein deficiency, lipoatrophic diabetes mellitus, Mauriac syndrome, hypopituitarism, hypogonadism, polycystic ovarian syndrome;
- •Have a history of malignant tumors in the past 5 years, excluding malignant tumors that have been cured by the investigator's judgment;
- •Pregnant or lactating women.
Arms & Interventions
NASH with fibrosis
NASH patients with fibrosis receiving routine treatment
Outcomes
Primary Outcomes
1.Patient demography
Time Frame: Baseline
Gender (male, female) ，age (years)，time since pathological diagnosis of NASH (months)， proportion of comorbidities
2.The proportion of 4 NASH treatment modalities at baseline and follow-up
Time Frame: up to 3-year follow-up
NASH treatment modalities include：Drug treatment，Non-drug treatment，Combined treatment and No treatment received
3.NASH Knowledge, Belief and Practice Questionnaire responses at baseline and follow-up
Time Frame: up to 3-year follow-up
Describe the responses of patients to the NASH Knowledge, Belief and Practice Questionnaire at baseline and follow-up periods. The questionnaire includes NASH patients' knowledge, attitude, and behavior towards NASH disease, NASH-related medical service needs, expectations, satisfaction, and does not involve the evaluation of scores.
Secondary Outcomes
- 2.The annual frequency of liver related visits(up to 3-year follow-up)
- 3.Total liver-related cost(up to 3-year follow-up)
- 1. The correlation between non-invasive diagnostic methods and pathological results of liver biopsy in NASH patients(up to 3-year follow-up)